Mechanisms and modifications of naturally occurring host defense peptides for anti-HIV microbicide development

Current HIV Research

Volumn 10, Issue 1, 2012, Pages 61-72

  Eade, Colleen R ^a   Wood, Matthew P ^a   Cole, Alexander M ^a  

^a UNIVERSITY OF CENTRAL FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Defensin; HIV transmission; Host defense peptides; Microbicide development; Modification of peptides

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CAERIN 1.1; CAERIN 1.9; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CECROPIN A; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DEFENSIN 1; DEFENSIN 2; DEFENSIN 3; DERMASEPTIN S4; GLYCOPROTEIN GP 120; GPNP; GRIFFITHSIN; HBD 2; HBD 3; HNP 4; MACULATIN 1.1; MAXIMIN 3; MELITTIN; MICROBICIDE; POLYPEPTIDE ANTIBIOTIC AGENT; POLYPHEMUSIN II; PONERICIN L2; PROTEGRIN 1; RATNP 4; RBNP 1; SPINIGERIN; TACHYPLESIN I; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IC 50; INFECTION PREVENTION; LYSOSOME; PROTEIN BINDING; PROTEIN MODIFICATION; VIRION; VIRUS ENTRY; VIRUS ENVELOPE; VIRUS INHIBITION;

ANTI-INFECTIVE AGENTS, LOCAL; ANTI-RETROVIRAL AGENTS; DEFENSINS; DRUG DESIGN; HIV INFECTIONS; HIV-1; HUMANS; PEPTIDES;

EID: 84857136095     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/157016212799304580     Document Type: Article

References (97)

1. UNAIDS. Global Report: UNAIDS Report on the Global AIDS Epidemic [homepage on the Internet]. c2010 [updated 2010; cited 2010 Sept 12]. Available from: http://www.unaids.org/globalreport/documents/20101123_GlobalReport_full_en.pdf
2. Mauck C, Ballagh S, Creinin M, et al. Six-day randomized safety trial of intravaginal lime juice. J Acquir Immune Defic Syndr 2008; 49(3): 243-250.
3. Van Damme L, Ramjee G, Alary M, et al. Effectiveness of COL- 1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002; 360(9338): 971-977.
4. Lederman S, Gulick R, Chess L. Dextran sulfate and heparin interact with CD4 molecules to inhibit the binding of coat protein (gp120) of HIV. J Immunol 1989; 143(4): 1149-1154.
5. Pirrone V, Wigdahl B, Krebs F. The rise and fall of polyanionic inhibitors of the human immunodeficiency virus type 1. Antiviral Res 2011; 90(3): 168-182.
6. McCormack S, Ramjee G, Kamali A, et al. PRO2000 vaginal gel for prevention of HIV-1 infection (Microbicides Development Programme 301): a phase 3, randomised, double-blind, parallelgroup trial. Lancet 2010; 376(9749): 1329-1337.
7. Abdool Karim Q, Abdool Karim S, Frohlich J, et al. Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women. Science 2010; 329(5996): 1168-1174.
8. Grant R, Lama J, Anderson P, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363(27): 2587-2599.
9. Metzner K, Rauch P, Braun P, et al. Prevalence of key resistance mutations K65R, K103N, and M184V as minority HIV-1 variants in chronically HIV-1 infected, treatment-naive patients. J Clin Virol 2011; 50(2): 156-161.
10. Wang G, Li X, Wang Z. APD2: the updated antimicrobial peptide database and its application in peptide design. Nucleic Acids Res 2009; 37: D933-D937.
11. Wang C, Colgrave M, Gustafson K, et al. Anti-HIV cyclotides from the Chinese medicinal herb Viola yedoensis. J Nat Prod 2008; 71(1): 47-52.
12. Bourinbaiar A, Krasinski K, Borkowsky W. Anti-HIV effect of gramicidin in vitro: potential for spermicide use. Life Sci 1994; 54(1): PL5-PL9.
13. Gustafson K, Sowder R, Henderson L, et al. Circulins A and B: Novel HIV-Inhibitory Macrocyclic Peptides from the Tropical Tree Chassalia parvifolia. J Am Chem Soc 1994; 116: 9337-9338.
14. Orivel J, Redeker V, Le Caer J, et al. Ponericins, new antibacterial and insecticidal peptides from the venom of the ant Pachycondyla goeldii. J Biol Chem 2001; 276(21): 17823-17829.
15. VanCompernolle S, Taylor R, Oswald-Richter K, et al. Antimicrobial peptides from amphibian skin potently inhibit human immunodeficiency virus infection and transfer of virus from dendritic cells to T cells. J Virol 2005; 79(18): 11598-606.
16. Lorin C, Saidi H, Belaid A, et al. The antimicrobial peptide dermaseptin S4 inhibits HIV-1 infectivity in vitro. Virology 2005; 334(2): 264-275.
17. Marcotte I, Wegener K, Lam Y, et al. Interaction of antimicrobial peptides from Australian amphibians with lipid membranes. Chem Phys Lipids 2003; 122(1/2): 107-120.
18. Lee-Huang S, Maiorov V, Huang P, et al. Structural and functional modeling of human lysozyme reveals a unique nonapeptide, HL9, with anti-HIV activity. Biochemistry 2005; 44(12): 4648-4655.
19. Zairi A, Tangy F, Bouassida K, Hani K. Dermaseptins and magainins: antimicrobial peptides from frogs' skin-new sources for a promising spermicides microbicides-a mini review. J Biomed Biotechnol 2009; 2009: 452-567.
20. Epand R, Epand R. Bacterial membrane lipids in the action of antimicrobial agents. J Pept Sci 2011; 17(5): 298-305.
21. Lai Y, Gallo R. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 2009; 30(3):131-141.
22. Micewicz E, Cole A, Jung C, et al. Grifonin-1: A Small HIV-1 Entry Inhibitor Derived from the Algal Lectin, Griffithsin. PLoS ONE 2010; 5(12): e14360.
23. Wang W, Cole A, Hong T, Waring A, Lehrer R. Retrocyclin, an antiretroviral theta-defensin, is a lectin. J Immunol 2003; 170(9): 4708-4716.
24. Wu Z, Cocchi F, Gentles D, et al. Human neutrophil alpha-defensin 4 inhibits HIV-1 infection in vitro. FEBS Letters 2005; 579(1): 162-166.
25. Balzarini J. Inhibition of HIV entry by carbohydrate-binding proteins. Antiviral Res 2006; 71(2-3): 237-247.
26. Mori T, O'Keefe B, Sowder R, et al. Isolation and characterization of griffithsin, a novel HIV-inactivating protein, from the red alga Griffithsia sp. J Biol Chem 2005; 280(10): 9345-9353.
27. Murakami T, Zhang T, Koyanagi Y, et al. Inhibitory mechanism of the CXCR4 antagonist T22 against human immunodeficiency virus type 1 infection. J Virol 1999; 73(9): 7489-7496.
28. Quiñones-Mateu M, Lederman M, Feng Z, et al. Human epithelial beta-defensins 2 and 3 inhibit HIV-1 replication. AIDS 2003; 17(16): F39-F48.
29. Owen S, Rudolph D, Wang W, et al. RC-101, a retrocyclin-1 analogue with enhanced activity against primary HIV type 1 isolates. AIDS Res Hum Retroviruses 2004; 20(11): 1157-1165.
30. Münch J, Ständker L, Adermann K, et al. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide. Cell 2007; 129(2): 263-275.
31. Cole A, Yang O, Warren A, et al. HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41. J Immunol 2006; 176(11): 6900-6905.
32. Gallo S, Wang W, Rawat S, et al. Theta-defensins prevent HIV-1 Env-mediated fusion by binding gp41 and blocking 6-helix bundle formation. J Biol Chem 2006; 281(27): 18787-18792.
33. Fuhrman C, Warren A, Waring A, et al. Retrocyclin RC-101 overcomes cationic mutations on the heptad repeat 2 region of HIV-1 gp41. FEBS J 2007; 274(24): 6477-6487.
34. Cole A, Patton D, Rohan L, et al. The formulated microbicide RC- 101 was safe and antivirally active following intravaginal application in pigtailed macaques. PLoS ONE 2010; 5(11): e15111.
35. Cole A, Herasimtschuk A, Gupta P, et al. The retrocyclin analogue RC-101 prevents human immunodeficiency virus type 1 infection of a model human cervicovaginal tissue construct. Immunology 2007; 121(1): 140-145.
36. Marchand C, Krajewski K, Lee H, et al. Covalent binding of the natural antimicrobial peptide indolicidin to DNA abasic sites. Nucleic Acids Res 2006; 34(18): 5157-5165.
37. Wong J, Legowska A, Rolka K, et al. Effects of cathelicidin and its fragments on three key enzymes of HIV-1. Peptides 2011.
38. Steinstraesser L, Tippler B, Mertens J, et al. Inhibition of early steps in the lentiviral replication cycle by cathelicidin host defense peptides. Retrovirology 2005; 2: 2.
39. Robinson W, McDougall B, Tran D, Selsted M. Anti-HIV-1 activity of indolicidin, an antimicrobial peptide from neutrophils. J Leukoc Biol 1998; 63(1): 94-100.
40. Wang G, Watson K, Peterkofsky A, Buckheit R. Identification of novel human immunodeficiency virus type 1-inhibitory peptides based on the antimicrobial peptide database. Antimicrob Agents Chemother 2010; 54(3): 1343-1346.
41. Ganz T. Antimicrobial polypeptides. J Leukoc Biol 2004; 75(1): 34-38.
42. Nabel G, Baltimore D. An inducible transcription factor activates expression of human immunodeficiency virus in T cells. Nature 1987; 326(6114): 711-713.
43. Barcellini W, Colombo G, La Maestra L, et al. Alpha-melanocytestimulating hormone peptides inhibit HIV-1 expression in chronically infected promonocytic U1 cells and in acutely infected monocytes. J Leukoc Biol 2000; 68(5): 693-699.
44. Emau P, Tian B, O'keefe B, et al. Griffithsin, a potent HIV entry inhibitor, is an excellent candidate for anti-HIV microbicide. J Med Primatol 2007; 36(4/5): 244-253.
45. Xu Y, Tamamura H, Arakaki R, et al. Marked increase in anti-HIV activity, as well as inhibitory activity against HIV entry mediated by CXCR4, linked to enhancement of the binding ability of tachyplesin analogs to CXCR4. AIDS Res Hum Retroviruses 1999; 15(5): 419-427.
46. DeMarco S, Henze H, Lederer A, et al. Discovery of novel, highly potent and selective beta-hairpin mimetic CXCR4 inhibitors with excellent anti-HIV activity and pharmacokinetic profiles. Bioorg Med Chem 2006; 14(24): 8396-8404.
47. Tamamura H, Imai M, Ishihara T, et al. Pharmacophore identification of a chemokine receptor (CXCR4) antagonist, T22 ([Tyr(5,12), Lys7]-polyphemusin II), which specifically blocks T cell-line-tropic HIV-1 infection. Bioorg Med Chem 1998; 6(7): 1033-1041.
48. Tamamura H, Xu Y, Hattori T, et al. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140. Bioorg Med Chem 1998; 253(3): 877-882.
49. Tamamura H, Omagari A, Oishi S, et al. Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes. Bioorg Med Chem Lett 2000; 10(23): 2633-2637.
50. Tamamura H, Omagari A, Hiramatsu K, et al. Certification of the critical importance of L-3-(2-naphthyl)alanine at position 3 of a specific CXCR4 inhibitor, T140, leads to an exploratory performance of its downsizing study. Bioorg Med Chem 2002; 10(5): 1417-1426.
51. Tam J, Lu Y. A biomimetic strategy in the synthesis and fragmentation of cyclic protein. Protein Sci 1998; 7(7): 1583-1592.
52. Salazar-Gonzalez J, Salazar M, Keele B, et al. Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. J Exp Med 2009; 206(6): 1273-1289.
53. Keele B, Giorgi E, Salazar-Gonzalez J, et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA 2008; 105(21): 7552-7557.
54. Burkhart B, Gassman R, Langs D, et al.Gramicidin D conformation, dynamics and membrane ion transport. Biopolymers 1999; 51(2): 129-144.
55. Owen S, Rudolph D, Wang W, et al. A theta-defensin composed exclusively of D-amino acids is active against HIV-1. J Pept Res 2004; 63(6): 469-476.
56. Kokryakov V, Harwig S, Panyutich E, et al. Protegrins: leukocyte antimicrobial peptides that combine features of corticostatic defensins and tachyplesins. FEBS Letters 1993; 327(2): 231-236.
57. Tamamura H, Murakami T, Horiuchi S, et al. Synthesis of protegrin-related peptides and their antibacterial and anti-human immunodeficiency virus activity. Chem Pharm Bull 1995; 43(5): 853-858.
58. Tam J, Wu C, Yang J. Membranolytic selectivity of cystinestabilized cyclic protegrins. Eur J Biochem 2000; 267(11): 3289-3300.
59. Neff C, Kurisu T, Ndolo T, Fox K, Akkina R. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice. PLoS ONE 2011; 6(6): e20209.
60. Daniele M, Ruiz F, Pascual L, Barberis L. Ureaplasma urealyticum and Mycoplasma hominis Sensitivity to Bacteriocins Produced by Two Lactobacilli Strains. Curr Microbiol 2011; 63(4): 360-365.
61. Atassi F, Servin A. Individual and co-operative roles of lactic acid and hydrogen peroxide in the killing activity of enteric strain Lactobacillus johnsonii NCC933 and vaginal strain Lactobacillus gasseri KS120.1 against enteric, uropathogenic and vaginosisassociated pathogens. FEMS Microbiol Lett 2010; 304(1): 29-38.
62. Klebanoff S, Coombs R. Viricidal effect of Lactobacillus acidophilus on human immunodeficiency virus type 1: possible role in heterosexual transmission. J Exp Med 1991; 174(1): 289-292.
63. Dimitonova S, Danova S, Serkedjieva J, Bakalov B. Antimicrobial activity and protective properties of vaginal lactobacilli from healthy Bulgarian women. Anaerobe 2007; 13(5-6): 178-184.
64. Atashili J, Poole C, Ndumbe P, Adimora A, Smith J. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. AIDS 2008; 22(12): 1493-1501.
65. Secchi M, Xu Q, Lusso P, Vangelista L. The superior folding of a RANTES analogue expressed in lactobacilli as compared to mammalian cells reveals a promising system to screen new RANTES mutants. Protein Expr Purif 2009; 68(1): 34-41.
66. Pusch O, Kalyanaraman R, Tucker L, et al. An anti-HIV microbicide engineered in commensal bacteria: secretion of HIV-1 fusion inhibitors by lactobacilli. AIDS 2006; 20(15): 1917-1922.
67. Stapleton A, Au-Yeung M, Hooton T, et al. Randomized, placebocontrolled phase 2 trial of a Lactobacillus crispatus probiotic given intravaginally for prevention of recurrent urinary tract infection. Clin Infect Dis 2011; 52(10): 1212-1217.
68. Lagenaur L, Sanders-Beer B, Brichacek B, et al. Prevention of vaginal SHIV transmission in macaques by a live recombinant Lactobacillus. Mucosal Immunol 2011.
69. Wachinger M, Kleinschmidt A, Winder D, et al. Antimicrobial peptides melittin and cecropin inhibit replication of human immunodeficiency virus 1 by suppressing viral gene expression. J Gen Virol 1998; 79 (Pt 4): 731-740.
70. Dürr U, Sudheendra U, Ramamoorthy A. LL-37, the only human member of the cathelicidin family of antimicrobial peptides. Biochim Biophys Acta - Biomembranes 2006; 1758(9): 1408-1425.
71. Johansson J, Gudmundsson G, Rottenberg M, Berndt K, Agerberth B. Conformation-dependent antibacterial activity of the naturally occurring human peptide LL-37. J Biol Chem 1998; 273(6): 3718-3724.
72. Wang G, Watson KM, Buckheit RW Jr. Anti-human immunodeficiency virus type 1 activities of antimicrobial peptides derived from human and bovine cathelicidins. Antimicrob Agents Chemother 2008; 52(9): 3438-3440.
73. Mor A, Nicolas P. Isolation and structure of novel defensive peptides from frog skin. Eur J Biochem 1994; 219(1-2): 145-154.
74. Lai R, Zheng Y, Shen J, et al. Antimicrobial peptides from skin secretions of Chinese red belly toad Bombina maxima. Peptides 2002; 23(3): 427-435.
75. Landon C, Meudal H, Boulanger N, Bulet P, Vovelle F. Solution structures of stomoxyn and spinigerin, two insect antimicrobial peptides with an alpha-helical conformation. Biopolymers 2006; 81(2): 92-103.
76. Nakashima H, Yamamoto N, Masuda M, Fujii N. Defensins inhibit HIV replication in vitro. AIDS 1993; 7(8): 1129.
77. Selsted M, Harwig S. Purification, primary structure, and antimicrobial activities of a guinea pig neutrophil defensin. Infect Immun 1987; 55(9): 2281-2286.
78. Ganz T, Rayner J, Valore E, et al. The structure of the rabbit macrophage defensin genes and their organ-specific expression. J Immunol 1989; 143(4): 1358-1365.
79. Selsted M, Brown D, DeLange R, Lehrer R. Primary structures of MCP-1 and MCP-2, natural peptide antibiotics of rabbit lung macrophages. J Biol Chem 1983; 258(23): 14485-14489.
80. Selsted M, Brown D, DeLange R, Harwig S, Lehrer R. Primary structures of six antimicrobial peptides of rabbit peritoneal neutrophils. J Biol Chem 1985; 260(8):4579-4584.
81. Eisenhauer P, Harwig S, Szklarek D, et al. Purification and antimicrobial properties of three defensins from rat neutrophils. Infect Immun 1989; 57(7): 2021-2027.
82. Chang T, Francois F, Mosoian A, Klotman M. CAF-mediated human immunodeficiency virus (HIV) type 1 transcriptional inhibition is distinct from alpha-defensin-1 HIV inhibition. J Virol 2003; 77(12): 6777-6784.
83. Furci L, Sironi F, Tolazzi M, Vassena L, Lusso P. Alpha-defensins block the early steps of HIV-1 infection: interference with the binding of gp120 to CD4. Blood 2007; 109(7): 2928-2935.
84. Guo C, Tan N, Song L, Douglas S, Ho W. Alpha-defensins inhibit HIV infection of macrophages through upregulation of CCchemokines. AIDS 2004; 18(8): 1217-12178.
85. Klüver E, Schulz-Maronde S, Scheid S, et al. Structure-activity relation of human beta-defensin 3: influence of disulfide bonds and cysteine substitution on antimicrobial activity and cytotoxicity. Biochemistry 2005; 44(28): 9804-9816.
86. Hruby V, Sharma S, Toth K, et al. Design, synthesis, and conformation of superpotent and prolonged acting melanotropins. Ann N Y Acad Sci 1993; 680: 51-63.
87. Catania A, Cutuli M, Garofalo L, et al. The neuropeptide alpha-MSH in host defense. Ann N Y Acad Sci 2000; 917: 227-231.
88. Wang W, Owen S, Rudolph D, et al. Activity of alpha- and thetadefensins against primary isolates of HIV-1. J Immunol 2004; 173(1): 515-520.
89. Tang Y, Yuan J, Osapay G, et al. A cyclic antimicrobial peptide produced in primate leukocytes by the ligation of two truncated alpha-defensins. Science 1999; 286(5439): 498-502.
90. Tran D, Tran P, Tang Y, et al. Homodimeric theta-defensins from rhesus macaque leukocytes: isolation, synthesis, antimicrobial activities, and bacterial binding properties of the cyclic peptides. J Biol Chem 2002; 277(5): 3079-3084.
91. Tran D, Tran P, Roberts K, et al. Microbicidal properties and cytocidal selectivity of rhesus macaque theta defensins. Antimicrob Agents Chemother 2008; 52(3): 944-953.
92. Derua R, Gustafson K, Pannell L. Analysis of the disulfide linkage pattern in circulin A and B, HIV-inhibitory macrocyclic peptides. Biochem Biophys Res Commun 1996; 228(2): 632-638.
93. Lin P, Samanta H, Bechtold C, et al. Characterization of siamycin I, a human immunodeficiency virus fusion inhibitor. Antimicrob Agents Chemother 1996; 40(1): 133-138.
94. Tsunakawa M, Hu S, Hoshino Y, et al. Siamycins I and II, new anti-HIV peptides: I. Fermentation, isolation, biological activity and initial characterization. J Antibiot 1995; 48(5): 433-434.
95. Constantine K, Friedrichs M, Detlefsen D, et al. High-resolution solution structure of siamycin II: novel amphipathic character of a 21-residue peptide that inhibits HIV fusion. J Biomol NMR 1995; 5(3): 271-286.
96. Dubos R. Studies on a Bactericidal Agent Extracted from a Soil Bacillus: I. Preparation of the Agent. its Activity in vitro. J Exp Med 1939; 70(1): 1-10.
97. Koeppe R, Providence L, Greathouse D, et al. On the helix sense of gramicidin A single channels. Proteins 1992; 12(1): 49-62.